Application of Antisense Oligodeoxynucleotides (ODNs) for the Intervention of Kidney Disease
Enyu Imai(Takara (Japan)), Takenobu Kamada(The University of Osaka), Yoshitaka Isaka(The University of Osaka), Tetsuya Kaneko(The University of Osaka), Masaru Horio(The University of Osaka), Masaru Takenaka(The University of Osaka), Toshiki Moriyama(The University of Osaka), Yasufumi Kaneda(Osaka University), Yoshitaka Akagi(The University of Osaka), Yoshimasa Orita(The University of Osaka), Naohiko Ueda(Nara Institute of Science and Technology), Akio Ando(Osaka University of Health and Sport Sciences), Makoto Arai(Tokyo Metropolitan Institute of Medical Science)
Cited by 6
Related Papers
Improving polygenic prediction in ancestrally diverse populations
|Nature Genetics|2022|714
Hepatocyte growth factor gene therapy of liver cirrhosis in rats
|Nature Medicine|1999|588
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
|The Lancet Diabetes & Endocrinology|2019|372
Structure of pathological TDP-43 filaments from ALS with FTLD
|Nature|2021|326